Browse News
Filter News
Found 1,080 articles
-
Antibody Testing Market to Grow at 6.9% CAGR to be Worth $11.57Bn, Globally, by 2028 - Exclusive Report by The Insight Partners
5/26/2023
According to the new market research report "Antibody Testing Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product (Kits, Chemical and Reagents, Consumables);
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Membranous Nephropathy
5/25/2023
Human Immunology Biosciences (HI-Bio™) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for felzartamab, the company's investigational agent that is in development for the treatment of primary membranous nephropathy (PMN).
-
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
5/25/2023
Incyte announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology Annual Meeting held June 2-6 in Chicago, and at the European Hematology Association 2023 Hybrid Congress held in Frankfurt, Germany, from June 8-11 and virtually from June 14-15.
-
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
5/16/2023
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer.
-
Xencor Reports First Quarter 2023 Financial Results
5/8/2023
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.
-
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
5/4/2023
Vir Biotechnology, Inc. provided a corporate update and reported financial results for the first quarter ended March 31, 2023.
-
MorphoSys AG Reports First Quarter 2023 Financial Results
5/3/2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023.
-
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
5/2/2023
Incyte (Nasdaq:INCY) today reports 2023 first quarter financial results, and provides a status update on the Company’s clinical development portfolio.
-
Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
4/27/2023
MorphoSys AG will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST.
-
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
4/16/2023
MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG, and Incyte announced final five-year follow-up data from the Phase 2 L-MIND study showing that Monjuvi® plus lenalidomide followed by Monjuvi monotherapy provided prolonged, durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma.
-
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
4/13/2023
Editas Medicine, Inc. today announced the appointment of current Independent Director Emma Reeve as Chair of the Board, effective at the Company’s next annual stockholder meeting, currently scheduled for June 1.
-
HI-Bio Announces Positive Phase 2 Data on Felzartamab for the Treatment of Primary Membranous Nephropathy
4/11/2023
Human Immunology Biosciences announced positive data from two Phase 2 studies of felzartamab, M-PLACE and NewPLACE.
-
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
3/15/2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.
-
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
3/14/2023
Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida.
-
Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023
3/9/2023
MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).
-
MorphoSys AG announced Thursday it plans to drop its pre-clinical programs and cut 17% of its workforce in an effort to extend its cash runway.
-
MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
3/2/2023
MorphoSys AG announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure.
-
Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
3/2/2023
MorphoSys AG announces that it will stop work and operations on its pre-clinical research programs to optimize its cost structure.
-
Xencor Reports Fourth Quarter and Full Year 2022 Financial Results
2/23/2023
Xencor, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a review of recent business and clinical highlights.